Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease

2006

Glutaredoxin in the Lungs of Smokers and COPD Patients

Sample size: 50 publication 10 minutes Evidence: moderate

Author Information

Author(s): Mirva J Peltoniemi, Paula H Rytilä, Terttu H Harju, Ylermi M Soini, Kaisa M Salmenkivi, Lloyd W Ruddock, Vuokko L Kinnula

Primary Institution: University of Oulu, Oulu, Finland

The study investigates the role of glutaredoxins in the lungs of smokers and patients with chronic obstructive pulmonary disease (COPD).

Grx1 levels are decreased in COPD patients and are present in sputum supernatants, suggesting a role in regulating glutathione homeostasis.

Grx1 was mainly expressed in alveolar macrophages.
Grx1 levels decreased in COPD patients compared to healthy smokers.
Grx1 levels in sputum supernatants increased during acute exacerbations of COPD.

This study found that a protein called Grx1, which helps protect the lungs, is lower in people with severe lung disease from smoking.

The study used immunohistochemical and Western blot analyses on lung specimens and induced sputum from various groups.

The study does not assess the functional activity of Grx1 in vivo.

Included non-smokers, smokers, and COPD patients across different stages.

p = 0.021; p = 0.045; p = 0.022; p = 0.013; p = 0.051

p<0.05

Access the complete publication on the publisher's website